setrusumab – Patient Worthy

rawpixel / Pixabay

The First Osteogenesis Imperfecta Patient Has Been Dosed in a Novel Phase 2/3 Investigation

Post author:Trudy Horsting
Post published:May 9, 2022
Post category:Osteogenesis Imperfecta

Ultragenyx Pharmaceutical Inc. has just announced the first dosing in their Phase 2/3 trial investigating setrusumab (UX143) as a treatment for osteogenesis imperfecta (OI) patients. This trial is called Orbit,…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

The First Osteogenesis Imperfecta Patient Has Been Dosed in a Novel Phase 2/3 Investigation

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More